Collplant Biotechnologies LTD (CLGN) — 6-K Filings

All 6-K filings from Collplant Biotechnologies LTD. Browse 27 Foreign Current Report reports with AI-powered summaries and risk analysis.

6-K Filings (27)

CollPlant Biotechnologies Files December 2025 6-K Report — Dec 31, 2025 Risk: low
CollPlant Biotechnologies Ltd. filed a Form 6-K for the month of December 2025. This report is for a foreign private issuer and is incorporated by reference int
CollPlant Biotechnologies Files November 2025 6-K Report — Nov 26, 2025 Risk: low
CollPlant Biotechnologies Ltd. filed a Form 6-K on November 26, 2025, reporting on their activities for the month of November 2025. The filing includes a press
CollPlant Expands rhCollagen Distribution Network — Oct 27, 2025 Risk: low
On October 27, 2025, CollPlant Biotechnologies Ltd. announced an expansion of its rhCollagen distribution network. The company issued a press release detailing
CollPlant's Vergenz Bio-Ink Shows High Success in Diabetic Foot Ulcer Trial — Oct 20, 2025 Risk: medium
On October 20, 2025, CollPlant Biotechnologies Ltd. issued a press release announcing the successful completion of a clinical trial for its Vergenz™ rhCollagen-
CollPlant Unveils Novel 3D Bioprinted Osteoarthritis Treatment — Oct 16, 2025 Risk: medium
On October 16, 2025, CollPlant Biotechnologies Ltd. announced the successful development of a first-in-kind fully humanized 3D bioprinted regenerative medicine
CollPlant Biotechnologies Files 6-K Report — Sep 30, 2025 Risk: low
CollPlant Biotechnologies Ltd. filed a Form 6-K on September 30, 2025, reporting for the month of September 2025. The filing is a report of a foreign private is
CollPlant Expands Vergenix Distribution — Sep 15, 2025 Risk: medium
On September 15, 2025, CollPlant Biotechnologies Ltd. announced an expansion of the distribution of its Vergenix® product line. This expansion will include new
CollPlant Seeks Nasdaq Upgrade — Sep 12, 2025 Risk: low
CollPlant Biotechnologies Ltd. submitted a voluntary application on September 12, 2025, to transfer the listing of its ordinary shares from the Nasdaq Capital M
CollPlant Biotechnologies Files 6-K Report — Aug 20, 2025 Risk: low
CollPlant Biotechnologies Ltd. filed a Form 6-K on August 20, 2025, reporting for the period ending June 30, 2025. The company, incorporated in Israel, operates
CollPlant Appoints Collagen Biomaterials Expert as CSO — Jul 14, 2025 Risk: low
CollPlant Biotechnologies Ltd. announced on July 14, 2025, the appointment of Dr. Elka Touitou as Chief Scientific Officer. Dr. Touitou, a recognized expert in
CollPlant Expands STEMCELL Collaboration — Jun 9, 2025 Risk: low
On June 9, 2025, CollPlant Biotechnologies Ltd. announced an expansion of its collaboration with STEMCELL Technologies Inc. This expanded agreement focuses on t
CollPlant Biotechnologies Secures European Patent for BioInk — Jun 4, 2025 Risk: low
CollPlant Biotechnologies Ltd. announced on June 4, 2025, that it has been granted a European patent for its "BioInk" technology. This patent covers the use of
CollPlant Biotechnologies Files June 2025 6-K Report — Jun 2, 2025 Risk: low
CollPlant Biotechnologies Ltd. filed a Form 6-K on June 2, 2025, reporting on its activities for the month of June 2025. The filing is a report of a foreign pri
CollPlant Biotechnologies Files May 2025 6-K Report — May 30, 2025 Risk: low
CollPlant Biotechnologies Ltd. filed a Form 6-K on May 30, 2025, reporting on its activities for the month of May 2025. The filing includes a press release, whi
CollPlant Biotechnologies Reports Q1 2025 Financials — May 28, 2025 Risk: low
CollPlant Biotechnologies Ltd. filed a Form 6-K on May 28, 2025, reporting its first quarter 2025 financial results and balance sheet and cash flow information.
CollPlant Bio's Collink.3D® Shows High Success in Bone Regeneration Study — Apr 15, 2025 Risk: medium
On April 15, 2025, CollPlant Biotechnologies Ltd. announced the successful completion of a clinical study for its Collink.3D® bio-ink, demonstrating significant
CollPlant Biotechnologies Files Form 6-K for February 2025 — Feb 24, 2025 Risk: low
CollPlant Biotechnologies Ltd. filed a Form 6-K on February 24, 2025, reporting for the month of February 2025. The filing incorporates by reference the first p
CollPlant Gets New Patent for Dermal Filler — Feb 12, 2025 Risk: low
CollPlant Biotechnologies Ltd. announced on February 12, 2025, that it has been granted an additional patent for its photocurable dermal filler program. This pa
CollPlant Biotechnologies Files 6-K with Q3 2024 Financials — Nov 27, 2024 Risk: medium
CollPlant Biotechnologies Ltd. filed a Form 6-K on November 27, 2024, reporting financial results for the three- and nine-month periods ended September 30, 2024
CollPlant Biotechnologies Files September 2024 6-K Report — Sep 25, 2024 Risk: low
CollPlant Biotechnologies Ltd. filed a Form 6-K on September 25, 2024, to report on its activities for the month of September 2024. The filing is a report of a
CollPlant Biotechnologies Files August 2024 6-K Report — Aug 20, 2024 Risk: low
CollPlant Biotechnologies Ltd. filed a Form 6-K on August 20, 2024, reporting on its activities for the month of August 2024. The filing is a report of a foreig
CollPlant to Acquire Nano-X Imaging for $126M — Aug 19, 2024 Risk: medium
CollPlant Biotechnologies Ltd. announced on August 19, 2024, that it has entered into a binding agreement to acquire Nano-X Imaging Ltd. for approximately $126
CollPlant Biotechnologies Unveils Inaugura 3D Bioprinting Platform — Jul 29, 2024 Risk: medium
On July 29, 2024, CollPlant Biotechnologies Ltd. issued a press release announcing the unveiling of its "Inaugura" 3D bioprinting platform. This platform is des
CollPlant to Acquire Nano-X Imaging for $126M — Jun 6, 2024 Risk: medium
CollPlant Biotechnologies Ltd. announced on June 6, 2024, that it has entered into a binding agreement to acquire Nano-X Imaging Ltd. for approximately $126 mil
CollPlant Biotechnologies Reports Q1 2024 Financial Results — May 29, 2024 Risk: low
CollPlant Biotechnologies Ltd. filed a Form 6-K on May 29, 2024, reporting its first quarter financial results. The filing details the company's financial perfo
CollPlant 6-K Reports 2023 Shareholder Letter — Feb 15, 2024 Risk: medium
CollPlant Biotechnologies Ltd. filed a Form 6-K on February 15, 2024, to report a press release that was issued on February 15, 2023. The press release was titl
CollPlant Begins Preclinical Trials for Regenerative Breast Implants — Jan 2, 2024
CollPlant Biotechnologies Ltd. announced on January 2, 2024, that it has started preclinical trials for its commercial-size, regenerative breast implants. This

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX